Assessment of Antifungal Pharmacodynamics

Overview

Journal J Fungi (Basel)

Date 2023 Feb 25

PMID 36836307

Authors

Alex Howard

William Hope

Affiliations

Soon will be listed here.

Abstract

Pharmacokinetic-pharmacodynamic (PK-PD) analysis is of central importance to the progress of an antifungal agent into clinical use. It is crucial to ensure that preclinical studies give the best possible prediction of the way drugs are likely to behave in a clinical setting. This review details the last 30 years of progress in terms of disease model design, efficacy outcome selection and translational modelling in antifungal PK-PD studies. The principles of how PK-PD parameters inform current clinical practice are also discussed, including a review of how these apply to existing and novel agents.

Citing Articles

Miltefosine: A Repurposing Drug against Mucorales Pathogens.

Xisto M, Rollin-Pinheiro R, Rochetti V, Castro-Almeida Y, Borba-Santos L, Santos-Freitas G J Fungi (Basel). 2023; 9(12).

PMID: 38132767 PMC: 10744482. DOI: 10.3390/jof9121166.

References

Schmitt-Hoffmann A, Roos B, Heep M, Schleimer M, Weidekamm E, Brown T . Single-ascending-dose pharmacokinetics and safety of the novel broad-spectrum antifungal triazole BAL4815 after intravenous infusions (50, 100, and 200 milligrams) and oral administrations (100, 200, and 400 milligrams) of its prodrug, BAL8557, in.... Antimicrob Agents Chemother. 2005; 50(1):279-85. PMC: 1346775. DOI: 10.1128/AAC.50.1.279-285.2006. View

Box H, Livermore J, Johnson A, Mcentee L, Felton T, Whalley S . Pharmacodynamics of Isavuconazole in a Dynamic In Vitro Model of Invasive Pulmonary Aspergillosis. Antimicrob Agents Chemother. 2015; 60(1):278-87. PMC: 4704219. DOI: 10.1128/AAC.01364-15. View

Bowman J, Abruzzo G, Anderson J, Flattery A, Gill C, Pikounis V . Quantitative PCR assay to measure Aspergillus fumigatus burden in a murine model of disseminated aspergillosis: demonstration of efficacy of caspofungin acetate. Antimicrob Agents Chemother. 2001; 45(12):3474-81. PMC: 90856. DOI: 10.1128/AAC.45.12.3474-3481.2001. View

Becker M, de Marie S, Willemse D, Verbrugh H . Quantitative galactomannan detection is superior to PCR in diagnosing and monitoring invasive pulmonary aspergillosis in an experimental rat model. J Clin Microbiol. 2000; 38(4):1434-8. PMC: 86459. DOI: 10.1128/JCM.38.4.1434-1438.2000. View

Louie A, Deziel M, Liu W, Drusano M, Gumbo T, Drusano G . Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity. Antimicrob Agents Chemother. 2005; 49(12):5058-68. PMC: 1315924. DOI: 10.1128/AAC.49.12.5058-5068.2005. View

Cannon R, Lamping E, Holmes A, Niimi K, Baret P, Keniya M . Efflux-mediated antifungal drug resistance. Clin Microbiol Rev. 2009; 22(2):291-321, Table of Contents. PMC: 2668233. DOI: 10.1128/CMR.00051-08. View

Scholz I, Oberwittler H, Riedel K, Burhenne J, Weiss J, Haefeli W . Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype. Br J Clin Pharmacol. 2009; 68(6):906-15. PMC: 2810802. DOI: 10.1111/j.1365-2125.2009.03534.x. View

Wong B, Leal I, Feau N, Dale A, Uzunovic A, Hamelin R . Molecular assays to detect the presence and viability of Phytophthora ramorum and Grosmannia clavigera. PLoS One. 2020; 15(2):e0221742. PMC: 7001964. DOI: 10.1371/journal.pone.0221742. View

Petraitiene R, Petraitis V, Hope W, Mickiene D, Kelaher A, Murray H . Cerebrospinal fluid and plasma (1-->3)-beta-D-glucan as surrogate markers for detection and monitoring of therapeutic response in experimental hematogenous Candida meningoencephalitis. Antimicrob Agents Chemother. 2008; 52(11):4121-9. PMC: 2573149. DOI: 10.1128/AAC.00674-08. View

10.

Lewis R, Lund B, Klepser M, Ernst E, Pfaller M . Assessment of antifungal activities of fluconazole and amphotericin B administered alone and in combination against Candida albicans by using a dynamic in vitro mycotic infection model. Antimicrob Agents Chemother. 1998; 42(6):1382-6. PMC: 105608. DOI: 10.1128/AAC.42.6.1382. View

11.

Andes D, Safdar N, Marchillo K, Conklin R . Pharmacokinetic-pharmacodynamic comparison of amphotericin B (AMB) and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models. Antimicrob Agents Chemother. 2006; 50(2):674-84. PMC: 1366906. DOI: 10.1128/AAC.50.2.674-684.2006. View

12.

Gebremariam T, Gu Y, Singh S, Kitt T, Ibrahim A . Combination treatment of liposomal amphotericin B and isavuconazole is synergistic in treating experimental mucormycosis. J Antimicrob Chemother. 2021; 76(10):2636-2639. PMC: 8446914. DOI: 10.1093/jac/dkab233. View

13.

Hope W, Kruhlak M, Lyman C, Petraitiene R, Petraitis V, Francesconi A . Pathogenesis of Aspergillus fumigatus and the kinetics of galactomannan in an in vitro model of early invasive pulmonary aspergillosis: implications for antifungal therapy. J Infect Dis. 2007; 195(3):455-66. DOI: 10.1086/510535. View

14.

Arendrup M, Perlin D, Jensen R, Howard S, Goodwin J, Hope W . Differential in vivo activities of anidulafungin, caspofungin, and micafungin against Candida glabrata isolates with and without FKS resistance mutations. Antimicrob Agents Chemother. 2012; 56(5):2435-42. PMC: 3346593. DOI: 10.1128/AAC.06369-11. View

15.

Seyedmousavi S, Bruggemann R, Melchers W, Verweij P, Mouton J . Pharmacodynamics of anidulafungin against clinical Aspergillus fumigatus isolates in a nonneutropenic murine model of disseminated aspergillosis. Antimicrob Agents Chemother. 2012; 57(1):303-8. PMC: 3535895. DOI: 10.1128/AAC.01430-12. View

16.

Anastassopoulou C, Fuchs B, Mylonakis E . Caenorhabditis elegans-based model systems for antifungal drug discovery. Curr Pharm Des. 2011; 17(13):1225-33. PMC: 3719869. DOI: 10.2174/138161211795703753. View

17.

Lionakis M . Drosophila and Galleria insect model hosts: new tools for the study of fungal virulence, pharmacology and immunology. Virulence. 2011; 2(6):521-7. PMC: 3260546. DOI: 10.4161/viru.2.6.18520. View

18.

Lepak A, Zhao M, Andes D . Pharmacodynamic Evaluation of Rezafungin (CD101) against Candida auris in the Neutropenic Mouse Invasive Candidiasis Model. Antimicrob Agents Chemother. 2018; 62(11). PMC: 6201117. DOI: 10.1128/AAC.01572-18. View

19.

Al-Nakeeb Z, Sudan A, Jeans A, Gregson L, Goodwin J, Warn P . Pharmacodynamics of itraconazole against Aspergillus fumigatus in an in vitro model of the human alveolus: perspectives on the treatment of triazole-resistant infection and utility of airway administration. Antimicrob Agents Chemother. 2012; 56(8):4146-53. PMC: 3421583. DOI: 10.1128/AAC.00141-12. View

20.

Chang Y, Khanal Lamichhane A, Kwon-Chung K . Cryptococcus neoformans, Unlike Candida albicans, Forms Aneuploid Clones Directly from Uninucleated Cells under Fluconazole Stress. mBio. 2018; 9(6). PMC: 6282203. DOI: 10.1128/mBio.01290-18. View